Randomized Clinical Trials on the Efficacy and Safety of Tocilizumab in
Subjects with Rheumatoid Arthritis: A Systematic Review

Adel      Sadeq; Asim   Ahmed   Elnour; Azza      Ramadan; Israa   Yousif   Kidir; Judit      Don; Abdulla      Al Amoodi; Nadia      Al Mazrouei; Mohamed   A.   Baraka; Farah   Hamad   Farah; Maisoun      Alkaabi

Abstract

Background: The current therapy of Rheumatoid Arthritis (RA) is confronted with many challenges such as inadequate response, infection, and treatment failure.

Aim and Objective: The main objective was to assess the efficacy and safety of tocilizumab (TCZ) in subjects with RA using the available evidence from published randomized controlled trials.

Methods: The current systematic review was performed on nine randomized controlled trials from 2002 to 2016 for TCZ in subjects with rheumatoid arthritis. The primary outcomes were the clinical improvement in American College Rheumatology 20% (ACR20) or Disease Activity Score remission (DAS28), in addition to other outcomes such as ACR50 and ACR70 in the intention-to-treat population.

Results: We have conducted a systematic review on nine randomized controlled trials, with 4129 [100%] enrolled, of which 3248 [78.7%] were on the intention-to-treat. 2147 (66.1%) were treated with TCZ and 1101 (33.9%) have had received placebo or methotrexate or other conventional Disease- Modifying Anti-rheumatic Drugs (cDMARD) or biologic Disease-Modifying Anti-rheumatic Drugs (bDMARDs). In subjects taking TCZ with or without concomitant methotrexate, compared to placebo, subjects treated with TCZ 4 or 8 mg/kg were substantially and statistically significantly more likely than placebo or methotrexate to achieve the ACR20 and/or DAS28. There were no statistically significant differences in serious adverse events such as serious infection; however, subjects on TCZ were more likely to have increased lipid profiles.

Conclusion: TCZ mono-therapy or in combination with methotrexate is valuable in diminishing rheumatoid arthritis disease activity and improving disability. Treatment with TCZ was associated with a significant surge in cholesterol levels but no serious adverse effects. Randomized clinical trials with safety as the primary outcome are warranted to report these safety issues.

Keywords: Rheumatoid Arthritis (RA), Interleukin-6 inhibitor (IL-6), Tocilizumab (TCZ), randomized clinical trials, placebo, comparator, safety, efficacy.

Graphical Abstract

[1]
Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol Int  2021; 41(5): 863-77.
 [http://dx.doi.org/10.1007/s00296-020-04731-0] [PMID: 33175207]

[2]
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA  2018; 320(13): 1360-72.
 [http://dx.doi.org/10.1001/jama.2018.13103] [PMID: 30285183]

[3]
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken)  2021; 73(7): 924-39.
 [http://dx.doi.org/10.1002/acr.24596] [PMID: 34101387]

[4]
Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis  2017; 76(7): 1279-84.
 [http://dx.doi.org/10.1136/annrheumdis-2016-210561] [PMID: 28389552]

[5]
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med  2001; 345(15): 1098-104.
 [http://dx.doi.org/10.1056/NEJMoa011110] [PMID: 11596589]

[6]
Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol  2020; 72(1): 31-40.
 [http://dx.doi.org/10.1002/art.41095] [PMID: 31469238]

[7]
US Food and Drug Administration. Center for drug evaluation and research. Statistical review - clinical studies - olumiant (baricitinib) 2019. Available from: https://www.accessdata.fdagov/drugsatfda_docs/nda/2018/207924Orig1s000StatRpdf. (Accessed 1 August 2021)

[8]
Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis  2014; 73(1): 198-206.
 [http://dx.doi.org/10.1136/annrheumdis-2012-202603] [PMID: 23467636]

[9]
Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis  2018; 77(10): 1413-20.
 [http://dx.doi.org/10.1136/annrheumdis-2018-213289] [PMID: 29980576]

[10]
Putrik P, Ramiro S, Keszei AP, et al. Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Ann Rheum Dis  2016; 75(3): 540-6.
 [http://dx.doi.org/10.1136/annrheumdis-2014-206737] [PMID: 25630346]

[11]
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis  2017; 76(6): 960-77.
 [http://dx.doi.org/10.1136/annrheumdis-2016-210715] [PMID: 28264816]

[12]
Elnour AA. Protocol for systematic review and meta-analysis on the efficacy and safety of Tocilizumab. Sys Rev Pharm  2020; 11(11): 1050-61.
 [http://dx.doi.org/10.31838/srp.2020.11.151]

[13]
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev  2015; 4: 1.
 [http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]

[14]
Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? a meta-analysis of discriminant capacities. Ann Rheum Dis  2006; 65(12): 1602-7.
 [http://dx.doi.org/10.1136/ard.2005.048975] [PMID: 16504992]

[15]
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials  1996; 17(1): 1-12.
 [http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]

[16]
Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet  2016; 388(10042): 343-55.
 [http://dx.doi.org/10.1016/S0140-6736(16)30363-4] [PMID: 27287832]

[17]
Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol  2009; 19(1): 12-9.
 [http://dx.doi.org/10.3109/s10165-008-0125-1] [PMID: 18979150]

[18]
Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis  2008; 67(11): 1516-23.
 [http://dx.doi.org/10.1136/ard.2008.092932] [PMID: 18625622]

[19]
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum  2008; 58(10): 2968-80.
 [http://dx.doi.org/10.1002/art.23940] [PMID: 18821691]

[20]
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet  2008; 371(9617): 987-97.
 [http://dx.doi.org/10.1016/S0140-6736(08)60453-5] [PMID: 18358926]

[21]
Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis  2007; 66(9): 1162-7.
 [http://dx.doi.org/10.1136/ard.2006.068064] [PMID: 17485422]

[22]
Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum  2006; 54(9): 2817-29.
 [http://dx.doi.org/10.1002/art.22033] [PMID: 16947782]

[23]
Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum  2004; 50(6): 1761-9.
 [http://dx.doi.org/10.1002/art.20303] [PMID: 15188351]

[24]
Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum  2002; 46(12): 3143-50.
 [http://dx.doi.org/10.1002/art.10623] [PMID: 12483717]

[25]
Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm  2015; 21(5): 409-23.
 [http://dx.doi.org/10.18553/jmcp.2015.21.5.409] [PMID: 25943002]

[26]
Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet  2013; 381(9877): 1541-50.
 [http://dx.doi.org/10.1016/S0140-6736(13)60250-0] [PMID: 23515142]

[27]
Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken)  2013; 65(3): 362-71.
 [http://dx.doi.org/10.1002/acr.21847] [PMID: 22972745]

[28]
Ćalasan MB, van den Bosch OF, Creemers MC, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther  2013; 15(6): R217.
 [http://dx.doi.org/10.1186/ar4413] [PMID: 24345416]

[29]
Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken)  2014; 66(11): 1653-61.
 [http://dx.doi.org/10.1002/acr.22384] [PMID: 24942540]

[30]
Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis  2014; 73(1): 69-74.
 [http://dx.doi.org/10.1136/annrheumdis-2013-203523] [PMID: 23904473]

[31]
Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis  2016; 75(6): 1081-91.
 [http://dx.doi.org/10.1136/annrheumdis-2015-207628] [PMID: 26511996]

[32]
Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum  2011; 63(3): 609-21.
 [http://dx.doi.org/10.1002/art.30158] [PMID: 21360490]

[33]
Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis  2005; 64(2): 303-5.
 [http://dx.doi.org/10.1136/ard.2004.023119] [PMID: 15231512]

[34]
Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med  2004; 351(25): 2599-610.
 [http://dx.doi.org/10.1056/NEJMoa040967] [PMID: 15602020]

[35]
Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum  2005; 52(2): 412-20.
 [http://dx.doi.org/10.1002/art.20855] [PMID: 15692992]

[36]
Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gómez-Reino JJ. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol  2015; 67(1): 117-27.
 [http://dx.doi.org/10.1002/art.38894] [PMID: 25303044]

[37]
Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis  2013; 229(1): 174-81.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2013.04.031] [PMID: 23746537]

[38]
McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis  2015; 74(4): 694-702.
 [http://dx.doi.org/10.1136/annrheumdis-2013-204345] [PMID: 24368514]

Cite As

Current Reviews in Clinical and Experimental Pharmacology

Randomized Clinical Trials on the Efficacy and Safety of Tocilizumab in Subjects with Rheumatoid Arthritis: A Systematic Review

Abstract

Graphical Abstract